Aloric 100 Tablet

Aloric 100 Tablet is used for: Hyperuricaemia, Uric acid nephropathy, Cancer therapy-induced hyperuricaemia, Gout, Recurrent renal stones

Adult: PO Gout; Hyperuricaemia The initial dosage is 100 mg orally daily. Increase by 100 mg weekly increments until serum uric acid of 6 mg/dl or less is reached (maximum 800 mg daily). Hyperuricemia Associated with Cancer Therapy Prevention of hyperuricemia associated w/ chemotherapy treatment or enzyme disorders 300 mg to 800 mg orally daily, starting 2-3 days before cancer treatment. Recurrent Calcium Oxalate Calculi: The recommended initial dosage in patients with normal kidney function is 200 mg to 300 mg orally daily .

Hyperuricemia Associated with Cancer Therapy Pediatric patients: 100 mg/m2 orally every 8 hours to 12 hours (10 mg/kg/day, maximum 800 mg/day)

Renal impairment: eGFR Initial Dosage > 60 mL/minute: No dosage modification > 30 to 60 mL/minute: 50 mg daily > 15 to 30 mL/minute: 50 mg every other day 5 to 15 mL/minute: 50 mg twice weekly < 5 mL/minute: 50 mg once weekly

Administration Should be taken with food. Take immediately after meals.

Known hypersensitivity to allopurinol or to any of the ingredients of allopurinol tablets.; acute attack of gout.

Skin Rash and Hypersensitivity: Allopurinol has been associated with serious and sometimes fatal dermatological reactions. Discontinue Allopurinol Tablets at the first appearance of skin rash or other signs of hypersensitivity reaction. Gout Flares: May occur during initiation of treatment. Concurrent prophylactic treatment with colchicine or anti-inflammatory agents is recommended. Nephrotoxicity: Allopurinol may affect kidney function. Patients with decreased kidney function require lower doses of Allopurinol Tablets. Hepatoxicity: Cases of reversible hepatotoxicity have occurred. If signs and symptoms of hepatotoxicity develop, evaluate liver function. Myelosuppression: Bone marrow suppression has been reported with allopurinol. Potential Effect on Driving and Use of Machinery: Drowsiness, somnolence and dizziness have been reported in patients taking allopurinol. Monitoring Parameters Prior to initiating treatment assess serum uric acid level, complete blood count, chemistry panel, liver and kidney function tests. Prophylactic treatment for gout flares is recommended. Maintain fluid intake sufficient to yield a urinary output of at least 2 liters per day in adults and at least 2 liters/m2/day (or at least 100 mL/m2/hour) in pediatric patients.

Pregnancy Available limited published data on allopurinol use in pregnant women do not demonstrate a clear pattern or increase in frequency of adverse developmental outcomes. Among approximately 50 pregnancies described in published literature, 2 infants with major congenital malformations have been reported with following maternal allopurinol exposure. Advise pregnant women of the potential risk to a fetus Animal data Based on findings in animals, this drug may cause fetal harm when administered to a pregnant woman; adverse developmental outcomes described in exposed animals; this drug and its metabolite oxypurinol shown to cross placenta following administration of maternal allopurinol Reproductive studies performed in rats and rabbits at doses up to twenty times usual human dose (5 mg/kg per day) concluded that there was no impaired fertility or harm to fetus due to allopurinol; there is a published report of a study in pregnant mice given 50 or 100 mg/kg allopurinol intraperitoneally on gestation days 10 or 13; there were increased numbers of dead fetuses in dams given 100 mg/kg allopurinol but not in those given 50 mg/kg There were increased numbers of external malformations in fetuses at both doses of allopurinol on gestation day 10 and increased numbers of skeletal malformations in fetuses at both doses on gestation day 13; it cannot be determined whether this represented a fetal effect or an effect secondary to maternal toxicity; there are, however, no adequate or well controlled studies in pregnant women; because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed Lactation Allopurinol and oxypurinol are present in human milk; based on information from a single case report, allopurinol and its active metabolite, oxypurinol, were detected in the milk of a mother at five weeks postpartum at an estimated relative infant dose of 0.14 and 0.2 mg/kg of allopurinol and between 7.2 to 8 mg/kg of oxypurinol daily There was no report of effects of allopurinol on the breastfed infant or on milk production; because of potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatments with this drug and for one week after last dose

The following drugs may increase the risk of serious skin reactions: bendamustine, thiazide diuretics, ampicillin and amoxicillin. Capecitabine: Avoid concomitant use. Mercaptopurine or Azathioprine: Reduce mercaptopurine or azathioprine dose as recommended in the respective prescribing information. Pegloticase: Discontinue and refrain from initiating treatment with allopurinol tablets. Contraindicated (0) Serious - Use Alternative (12) azathioprine benazepril captopril didanosine enalapril perindopril pexidartinib pretomanid protamine ropeginterferon alfa 2b theophylline warfarin

Side effects of Allopurinol : 1-10% Rash (1.5%),Nausea (1.3%),Renal failure (1.2%),Vomiting (1.2%) Frequency Not Defined Amblyopia,Arthralgias,Blood dyscrasias,Bronchospasm,Cardiovascular abnormalities,Cataracts,Confusion,Decrease in libido,Dizziness,Ecchymosis,Electrolyte abnormalities,Epistaxis,Foot drop,Hematuria,Hepatotoxicity,Hypotonia,Iritis,Kidney function abnormality,Macular retinitis,Malaise,Neuritis,Pharyngitis,Pruritus,Skin edema,Stevens-Johnson syndrome,Sweating,Tinnitus Potentially Fatal: Stevens-Jonhson and/or Lyell's Syndrome (urticaria, fever, lymphadenopathy, arthralgia). Occasionally, thrombocytopaenia, agranulocytosis and aplastic anaemia.

Allopurinol is an inhibitor of the enzyme xanthine oxidase which converts hypoxanthine to xanthine then uric acid. The reduced production of uric acid relieves all symptoms associated with hyperuricaemia and gout. Inhibition of xanthine oxidase leads to accumulation of its substrates hypoxanthine and xanthine but since their renal clearance is more than 10 times that of uric acid, there is no risk of nephrolithiasis.

Aloric 100 100mg Tablet manufactured by G. A. Company Ltd.. Its generic name is Allopurinol. Aloric 100 is availble in Bangladesh. Farmaco BD drug index information on Aloric 100 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.